<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02017327</url>
  </required_header>
  <id_info>
    <org_study_id>LT2345-PIV-02/13</org_study_id>
    <secondary_id>2013-001250-10</secondary_id>
    <nct_id>NCT02017327</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Assessment of Monoprost® in Comparison With Lumigan® 0.01 % and Lumigan® 0.03% Unit Dose</brief_title>
  <official_title>Safety and Efficacy Assessment of Monoprost® in Comparison With Lumigan® 0.01% and Lumigan® 0.03% Unit Dose, in Patients With Primary Open Angle Glaucoma or Ocular Hypertension, Stabilized by Lumigan® 0.01% With Ocular Surface Intolerance</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Laboratoires Thea</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Laboratoires Thea</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary objective:

      The primary objective is to demonstrate the superiority of Monoprost® versus Lumigan® 0.01%
      and Lumigan® 0.03% Unit Dose in term of safety with respect to the assessment of conjunctival
      hyperaemia in the worse eye at Day 84.

      The conjunctival hyperaemia will be scored using the MacMonnies photographic scale (0 to 5).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Actual">July 2016</completion_date>
  <primary_completion_date type="Actual">July 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety With Respect to the Assessment of Conjunctival Hyperaemia in the Worse Eye</measure>
    <time_frame>Day 84</time_frame>
    <description>The primary endpoint is the change from baseline of conjunctival hyperaemia assessed on MacMonnies' 6 point ordinal scale, in the worse eye at the D84 visit. The primary statistical hypothesis tested is that Monoprost® is superior to Lumigan® 0.03% Unit Dose with regard to this primary endpoint, i.e. that in the worse eye the decrease from baseline in the MacMonnies 6 point ordinal scale is greater in the Monoprost® treated group than in the Lumigan® 0.03% Unit Dose group at the Day 84 visit.
The conjunctival hyperaemia will be scored using the &quot;McMonnies&quot; photographic scale (0 to 5). The minimum score is 0 corresponding to a low hyperaemia and the maximum score is 5 corresponding to a higher hyperaemia.
The Rows represent the number of participants with a change from Baseline to D84 corresponding to
&quot;decrease of 3 points&quot;
&quot;decrease of 2 points&quot;
&quot;no change&quot;,
&quot;increase of 2 points&quot;
&quot;increase of 1 point&quot; on Mc Monnies scale</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">379</enrollment>
  <condition>Primary Open Angle Glaucoma</condition>
  <condition>Ocular Hypertension</condition>
  <arm_group>
    <arm_group_label>Monoprost</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 drop in each eye once daily at 9.00 pm (± 1 hour) for 3 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lumigan 0.01%</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1 drop in each eye once daily at 9.00 pm (± 1 hour) for 3 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lumigan 0.03% Unit Dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1 drop in each eye once daily at 9.00 pm (± 1 hour) for 3 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Monoprost</intervention_name>
    <description>Monoprost®: Latanoprost 0.005% ophthalmic preparation is a sterile unpreserved oil-based solution for topical ophthalmic use. It is supplied in 0.30 ml single use polyethylene containers. The batch numbers and reanalysis dates will be stated in the certificate of analysis.</description>
    <arm_group_label>Monoprost</arm_group_label>
    <other_name>Latanoprost 0.005%</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lumigan 0.01%</intervention_name>
    <description>Lumigan® 0.01%: Bimatoprost eye drop solution is supplied in 3 ml multidose container.</description>
    <arm_group_label>Lumigan 0.01%</arm_group_label>
    <other_name>Bimatoprost 0.1mg/ml</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lumigan 0.03% Unit Dose</intervention_name>
    <description>Lumigan® 0.03% Unit Dose: Bimatoprost eye drop solution is supplied in 0.4 ml single use low density polyethylene (LDPE) containers.</description>
    <arm_group_label>Lumigan 0.03% Unit Dose</arm_group_label>
    <other_name>Bimatoprost 0.3mg/ML</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female aged ≥18 years old.

          -  Written informed consent.

          -  Association of the 3 following criteria:

               1. Both eyes have primary open angle glaucoma or ocular hypertension already treated
                  and controlled by mono-therapy of Lumigan® 0.01% since at least 3 months
                  (according to European Glaucoma Society guidelines).

               2. Intra Ocular Pressure ≤ 18 mm Hg in both eyes.

               3. With local intolerance signs in at least one eye defined by the association of:

        3.1 Hyperaemia = Grade (2) or (3) or (4) following the photographic MacMonnies scale.

        And 3.2.1 Presence of at least 2 symptoms with a level of severity ≥ 1 (= mild or moderate
        or severe) among the following 5 symptoms: irritation/burning, itching, tearing, eye
        dryness sensation, foreign body sensation.

        And/Or 3.2.2 Presence of at least 2 signs with a level of severity ≥ 1 (= mild or moderate
        or severe) among the following 3 signs: superficial punctate keratitis, blepharitis, eyelid
        skin darkness.

        Exclusion Criteria:

          -  - Presence of at least one severe objective sign among the following:

               -  Global ocular staining with Oxford (0-15) grading scheme &gt;12.

               -  Blepharitis (Grade 4: Very severe, i.e. eczematiform lesion).

          -  Any ocular hypertension other than primary ocular hypertension or primary chronic open
             angle glaucoma (such as congenital, angle closure glaucoma, secondary glaucoma).

          -  Visual field not performed or not available within the 6 months before inclusion
             visit.

          -  Fundus not performed or not available within the 6 months before inclusion visit.

          -  Advanced stage of glaucoma:

               -  Absolute defect in the ten degrees central point of the visual field.

               -  Severe visual field loss according to the investigator's best judgement.

               -  Risk of visual field worsening as a consequence of participation in the trial
                  according to the investigator's best judgement.

          -  Best far corrected visual acuity ≤ 1/10.

          -  History of trauma, infection, inflammation within the 3 months before inclusion visit.

          -  Ongoing or known history of ocular allergy and/or uveitis and/or viral infection.

          -  Severe dry eye (defined by severe epithelial erosions of the cornea and/or use of dry
             eye medication with a frequency exceeding 8 instillations / day).

          -  Corneal ulceration.

          -  Palpebral abnormalities not related to medical treatment study and incompatible with a
             good evaluation.

          -  Any abnormality preventing accurate assessment e.g. reliable tonometry measurement,
             visual field examination.

        Systemic/non ophthalmic/ exclusion criteria

          -  Non-controlled diabetic patient.

          -  Known or suspected hypersensitivity to one of the components of the study product.

          -  Any medical or surgical history, disorder or disease such as acute or chronic severe
             organic disease: hepatic, endocrine, neoplastic, haematological; immunosuppressive,
             infectious diseases, severe psychiatric illness, relevant cardiovascular
             abnormalities, etc… and/or any complicating factor or structural abnormality, judged
             by the investigator to be incompatible with the study.

        Specific exclusion criteria for women

          -  Pregnancy, lactation.

          -  Childbearing potential woman who is not using a reliable method of contraception (oral
             contraceptive, intra-uterine device, subcutaneous contraceptive implant, vaginal ring,
             patch) and is not surgically sterilised.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christophe Baudouin, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hopital des XV-XX</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Laboratoires Théa</name>
      <address>
        <city>Clermont ferrand</city>
        <zip>63000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>December 2, 2013</study_first_submitted>
  <study_first_submitted_qc>December 16, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 20, 2013</study_first_posted>
  <results_first_submitted>March 30, 2018</results_first_submitted>
  <results_first_submitted_qc>March 20, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">April 2, 2020</results_first_posted>
  <last_update_submitted>March 20, 2020</last_update_submitted>
  <last_update_submitted_qc>March 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
    <mesh_term>Ocular Hypertension</mesh_term>
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Latanoprost</mesh_term>
    <mesh_term>Bimatoprost</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>patients were enrolled at medical clinics from Dec 2013 to July 2016</recruitment_details>
      <pre_assignment_details>the number of patients enrolled in 379 but as the primary Endpoint is Safety, the Baseline population is based on the safety Set and it corresponds to 373 patients</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Monoprost</title>
          <description>1 drop in each eye once daily at 9.00 pm (± 1 hour) for 3 months.
Monoprost: Monoprost®: Latanoprost 0.005% ophthalmic preparation is a sterile unpreserved oil-based solution for topical ophthalmic use. It is supplied in 0.30 ml single use polyethylene containers. The batch numbers and reanalysis dates will be stated in the certificate of analysis.</description>
        </group>
        <group group_id="P2">
          <title>Lumigan 0.01% (Bimatoprost Eye Drop Solution)</title>
          <description>1 drop in each eye once daily at 9.00 pm (± 1 hour) for 3 months.
3-mL multidose containers</description>
        </group>
        <group group_id="P3">
          <title>Lumigan 0.03% UD (Bimatoprost Eye Drop Solution)</title>
          <description>one drop in each eye once daily at 9.00 pm (± 1 hour) in the inferior conjunctival cul-de-sac from D0 to D84.
0.4-mL single-use low density polyethylene (LDPE) containers.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="122"/>
                <participants group_id="P2" count="125"/>
                <participants group_id="P3" count="132"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="106"/>
                <participants group_id="P2" count="113"/>
                <participants group_id="P3" count="117"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="15"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Monoprost</title>
          <description>1 drop in each eye once daily at 9.00 pm (± 1 hour) for 3 months.
Monoprost: Monoprost®: Latanoprost 0.005% ophthalmic preparation is a sterile unpreserved oil-based solution for topical ophthalmic use. It is supplied in 0.30 ml single use polyethylene containers. The batch numbers and reanalysis dates will be stated in the certificate of analysis.</description>
        </group>
        <group group_id="B2">
          <title>Lumigan 0.01%</title>
          <description>1 drop in each eye once daily at 9.00 pm (± 1 hour) for 3 months.
Lumigan 0.01%: Lumigan® 0.01%: Bimatoprost eye drop solution is supplied in 3 ml multidose container.</description>
        </group>
        <group group_id="B3">
          <title>Lumigan 0.03% Unit Dose</title>
          <description>1 drop in each eye once daily at 9.00 pm (± 1 hour) for 3 months.
Lumigan 0.03% Unit Dose: Lumigan® 0.03% Unit Dose: Bimatoprost eye drop solution is supplied in 0.4 ml single use low density polyethylene (LDPE) containers.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="119"/>
            <count group_id="B2" value="124"/>
            <count group_id="B3" value="130"/>
            <count group_id="B4" value="373"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                    <measurement group_id="B2" value="44"/>
                    <measurement group_id="B3" value="48"/>
                    <measurement group_id="B4" value="138"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="73"/>
                    <measurement group_id="B2" value="80"/>
                    <measurement group_id="B3" value="82"/>
                    <measurement group_id="B4" value="235"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67.5" spread="9.9"/>
                    <measurement group_id="B2" value="67.4" spread="10.3"/>
                    <measurement group_id="B3" value="68.3" spread="10"/>
                    <measurement group_id="B4" value="67.7" spread="10.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="70"/>
                    <measurement group_id="B2" value="70"/>
                    <measurement group_id="B3" value="78"/>
                    <measurement group_id="B4" value="218"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                    <measurement group_id="B2" value="54"/>
                    <measurement group_id="B3" value="52"/>
                    <measurement group_id="B4" value="155"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>France</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="26"/>
                    <measurement group_id="B4" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="52"/>
                    <measurement group_id="B3" value="51"/>
                    <measurement group_id="B4" value="153"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="26"/>
                    <measurement group_id="B4" value="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Greece</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Safety With Respect to the Assessment of Conjunctival Hyperaemia in the Worse Eye</title>
        <description>The primary endpoint is the change from baseline of conjunctival hyperaemia assessed on MacMonnies' 6 point ordinal scale, in the worse eye at the D84 visit. The primary statistical hypothesis tested is that Monoprost® is superior to Lumigan® 0.03% Unit Dose with regard to this primary endpoint, i.e. that in the worse eye the decrease from baseline in the MacMonnies 6 point ordinal scale is greater in the Monoprost® treated group than in the Lumigan® 0.03% Unit Dose group at the Day 84 visit.
The conjunctival hyperaemia will be scored using the &quot;McMonnies&quot; photographic scale (0 to 5). The minimum score is 0 corresponding to a low hyperaemia and the maximum score is 5 corresponding to a higher hyperaemia.
The Rows represent the number of participants with a change from Baseline to D84 corresponding to
&quot;decrease of 3 points&quot;
&quot;decrease of 2 points&quot;
&quot;no change&quot;,
&quot;increase of 2 points&quot;
&quot;increase of 1 point&quot; on Mc Monnies scale</description>
        <time_frame>Day 84</time_frame>
        <population>the primary analysis was performed in the mSAF.(All randomised patients of the Safety set with at least one eligible eye and with any safety information on treatment.)</population>
        <group_list>
          <group group_id="O1">
            <title>Monoprost</title>
            <description>1 drop in each eye once daily at 9.00 pm (± 1 hour) for 3 months.
Monoprost: Monoprost®: Latanoprost 0.005% ophthalmic preparation is a sterile unpreserved oil-based solution for topical ophthalmic use. It is supplied in 0.30 ml single use polyethylene containers. The batch numbers and reanalysis dates will be stated in the certificate of analysis.</description>
          </group>
          <group group_id="O2">
            <title>Lumigan 0.01%</title>
            <description>1 drop in each eye once daily at 9.00 pm (± 1 hour) for 3 months.
Lumigan 0.01%: Lumigan® 0.01%: Bimatoprost eye drop solution is supplied in 3 ml multidose container.</description>
          </group>
          <group group_id="O3">
            <title>Lumigan 0.03% Unit Dose</title>
            <description>1 drop in each eye once daily at 9.00 pm (± 1 hour) for 3 months.
Lumigan 0.03% Unit Dose: Lumigan® 0.03% Unit Dose: Bimatoprost eye drop solution is supplied in 0.4 ml single use low density polyethylene (LDPE) containers.</description>
          </group>
        </group_list>
        <measure>
          <title>Safety With Respect to the Assessment of Conjunctival Hyperaemia in the Worse Eye</title>
          <description>The primary endpoint is the change from baseline of conjunctival hyperaemia assessed on MacMonnies' 6 point ordinal scale, in the worse eye at the D84 visit. The primary statistical hypothesis tested is that Monoprost® is superior to Lumigan® 0.03% Unit Dose with regard to this primary endpoint, i.e. that in the worse eye the decrease from baseline in the MacMonnies 6 point ordinal scale is greater in the Monoprost® treated group than in the Lumigan® 0.03% Unit Dose group at the Day 84 visit.
The conjunctival hyperaemia will be scored using the &quot;McMonnies&quot; photographic scale (0 to 5). The minimum score is 0 corresponding to a low hyperaemia and the maximum score is 5 corresponding to a higher hyperaemia.
The Rows represent the number of participants with a change from Baseline to D84 corresponding to
&quot;decrease of 3 points&quot;
&quot;decrease of 2 points&quot;
&quot;no change&quot;,
&quot;increase of 2 points&quot;
&quot;increase of 1 point&quot; on Mc Monnies scale</description>
          <population>the primary analysis was performed in the mSAF.(All randomised patients of the Safety set with at least one eligible eye and with any safety information on treatment.)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="112"/>
                <count group_id="O2" value="118"/>
                <count group_id="O3" value="124"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>change at D84 -3</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>change at D84 - 2</title>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>change at D84 -1</title>
                  <measurement_list>
                    <measurement group_id="O1" value="47"/>
                    <measurement group_id="O2" value="59"/>
                    <measurement group_id="O3" value="42"/>
                  </measurement_list>
                </category>
                <category>
                  <title>change at D84 0</title>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="39"/>
                    <measurement group_id="O3" value="38"/>
                  </measurement_list>
                </category>
                <category>
                  <title>change at D84 +1</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>change at D84 +2</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>missing data</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0045</p_value>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>3 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Monoprost</title>
          <description>1 drop in each eye once daily at 9.00 pm (± 1 hour) for 3 months.
Monoprost: Monoprost®: Latanoprost 0.005% ophthalmic preparation is a sterile unpreserved oil-based solution for topical ophthalmic use. It is supplied in 0.30 ml single use polyethylene containers. The batch numbers and reanalysis dates will be stated in the certificate of analysis.</description>
        </group>
        <group group_id="E2">
          <title>Lumigan 0.01%</title>
          <description>1 drop in each eye once daily at 9.00 pm (± 1 hour) for 3 months.
Lumigan 0.01%: Lumigan® 0.01%: Bimatoprost eye drop solution is supplied in 3 ml multidose container.</description>
        </group>
        <group group_id="E3">
          <title>Lumigan 0.03% Unit Dose</title>
          <description>1 drop in each eye once daily at 9.00 pm (± 1 hour) for 3 months.
Lumigan 0.03% Unit Dose: Lumigan® 0.03% Unit Dose: Bimatoprost eye drop solution is supplied in 0.4 ml single use low density polyethylene (LDPE) containers.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (18.1)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="124"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="130"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="124"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="130"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>intervetebral disk protrusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="130"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>prostate cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>breast neoplasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>metastatic colon cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="130"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>ureterolithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="130"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="124"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="130"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="130"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>All the results of the Trial are the sole and exclusive property of THEA, and cannot be used in whatever form without prior written agreement of THEA.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Director of medical operation</name_or_title>
      <organization>Laboratoires Thea</organization>
      <phone>+473985089</phone>
      <email>J.auger@laboratoires-thea.fr</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

